Women's Health Issues
Volume 19, Issue 2 , Pages 144-153 , March 2009

Women's Trust in and Use of Information Sources in the Treatment of Menopausal Symptoms

  • Sally A. Huston, PhD

      Affiliations

    • University of Georgia, College of Pharmacy, Athens, Georgia
    • Corresponding Author InformationCorrespondence to: Sally A. Huston, PhD, , 251 RC Wilson Pharmacy, Athens, GA 30602-2354; Phone: 706-542-1040; fax: 706-542-5228.
    • ,
  • Rebekah M. Jackowski, PharmD

      Affiliations

    • University of Arizona, College of Pharmacy, Tucson, Arizona
    • ,
  • Duane M. Kirking, PharmD, PhD

      Affiliations

    • University of Michigan, College of Pharmacy, Ann Arbor, Michigan

Received 29 August 2008 ,Revised 5 January 2009 ,Accepted 14 January 2009.

References 

  1. Andrist LC. The impact of media attention, family history, politics and maturation on women's decisions regarding hormone replacement therapy. Health Care for Women International. 1998;19:243–260
  2. Ayerst Laboratories . Premarin (conjugated estrogen tablets, USP) Patient Package Insert. Philadelphia: Wyeth-Ayerst Laboratories; 2002;
  3. Churchill GA, Iacobucci D. Marketing research: Methodological foundations. 9th ed.. Florence, KY: South-Western; 2004;
  4. Clinkingbeard C, Minton BA, Davis J, McDermott K. Women's knowledge about menopause, hormone replacement therapy (HRT), and interactions with healthcare providers: an exploratory study. Journal of Women's Health and Gender-Based Medicine. 1999;8:1097–1102
  5. Comrey AL, Lee HB. A first course in factor analysis. 2nd ed.. Hillsdale, NJ: Lawrence Erlbaum Associates; 1992;
  6. Dillman DA. Mail and Internet surveys. The tailored design method. 2nd ed.. New York: John Wiley & Sons, Inc; 2000;
  7. Frewer LJ, Howard C, Hedderly D, Shepherd R. What determines trust in information about food-related risks? Underlying psychological constructs. Risk Analysis. 1996;16:473–486
  8. Garamszegi C, Dennerstein E, Dudley E, Guthrie JR, Ryan M, Burger H. Menopausal status: Subjectively and objectively defined. Journal of Psychosomatic Obstetrics and Gynaecology. 1998;19:165–173
  9. Gilson L. Trust and the development of health care as a social institution. Social Science & Medicine. 2003;56:1453–1468
  10. Grady D. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow up (HERS II). JAMA. 2002;288:321–333
  11. Griffiths F. Women's decisions about whether or not to take hormone replacement therapy: Influence of social and medical factors. The British Journal of General Practice. 1995;45:477–480
  12. Griffiths F. Women's control and choice regarding HRT. Social Science and Medicine. 1999;49:469–481
  13. Guillemin M. Managing menopause: A critical feminist engagement. Scandinavian Journal of Public Health. 1999;27:273–278
  14. Hoffman M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas. 2005;52:11–17
  15. Huston SA. Understanding women's decisions about hormone replacement therapy. Ann Arbor: University of Michigan Press; 2003;
  16. Huston SA, Kirking DM, Shimp LA. Use, intentions, and beliefs about hormone replacement therapy in women with and without diabetes. Maturitas. 2006;55:58–68
  17. Ingebretsen, M. (2002, December 30). Top health stories of '02: the strange and important. The Wall Street Journal [online version]. Available from: http://online.wsj.com/article/0,SB104117561424046953,00.html.
  18. Keating NL, Cleary PD, Rossi AS, Zaslavskky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Annals of Internal Medicine. 1999;130:545–553
  19. Kennedy I. Patients are expert in their own field. British Medical Journal. 2003;326:1276–1277
  20. Korsgaard MA, Whitener EM, Brodt SE. Trust in the face of conflict: The role of managerial trustworthy behavior and organizational context. Journal of Applied Psychology. 2002;87:312–319
  21. Ma J, Drieling R, Stafford RS. US women desire greater professional guidance on hormone and alternative therapies for menopause symptom management. Menopause. 2006;13:506–516
  22. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary-artery calcification. New England Journal of Medicine. 2007;356:2591–2602
  23. McCrea FB. The politics of menopause: the “discovery” of a deficiency disease. Social Problems. 1983;31:111–123
  24. McIntosh J, Blalock SJ. Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. American Journal of Health-System Pharmacy. 2005;62:69–74
  25. Mechanic D. Changing medical organization and the erosion of trust. The Milbank Quarterly. 1996;74:171–189
  26. Mechanic D. Public trust and initiatives for new health care partnerships. The Milbank Quarterly. 1998;76:281–302
  27. Robinson JG, Folsom AR, Nabulsi AA, Watson R, Brancati FL, Cai J. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?. Diabetes Care. 1996;19:480–485
  28. Schonberg MA, Davis RB, Wee CC. After the Women's Health Initiative: Decision making and trust of women taking hormone therapy. Womens Health Issues. 2005;15:187–195
  29. Shojania, K.G., Mariani, S.M., & Lundberg, G.D. (2002). MedGenMed's selection of the top 10 medical/health stories of 2002. Available from: http://www.medscape.com/viewarticle/446310. Accessed December 24, 2002.
  30. Slovic P. Perceptions of risk: Reflections on the psychometric paradigm. In:  Krimsky S,  Golding D editor. Social theories of risk. Westport, CT: Praeger; 1992;p. 117–152
  31. Stafford RS, Saglam D, Causino N, Blumenthal D. Low rates of hormone replacement in visits to United States primary care physicians. American Journal of Obstetrics and Gynecology. 1997;177:381–387
  32. Suter E, Verhoef MJ, Bockmuehl C, Forest N, Bobey M, Armitage GD. Women's approaches to evaluating complementary and alternative therapies for menopausal symptoms. Canadian Family Physician. 2007;53:84–90
  33. Thompson W. Estrogen replacement therapy in practice: Trends and issues. American Journal of Obstetrics and Gynecology. 1995;173:990–993
  34. Tio J, LaCaze A, Cottrell WN. Ascertaining consumer perspectives of medication information sources using a modified repertory grid technique. Pharmacy World & Science. 2007;29:73–80
  35. Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. Journal of Bone and Mineral Research. 2006;21:765–771
  36. Watkins ES. Dispensing with aging: Changing rationales for long-term hormone replacement therapy, 1960-2000. Pharmacy in History. 2001;43:23–37
  37. Whitener EM, Brodt SE, Korsgaard MA, Werner J. Managers as initiators of trust: An exchange relationship framework for understanding managerial trustworthy behavior. Academy of Management Review. 1998;23:513–530
  38. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association. 2002;288:321–333

 Funded by the Upjohn Research Fund at the University of Michigan.

PII: S1049-3867(09)00003-6

doi: 10.1016/j.whi.2009.01.004

Women's Health Issues
Volume 19, Issue 2 , Pages 144-153 , March 2009

Article Tools